Abstract
Purpose
To assess the diagnostic performance of magnetic resonance imaging (MRI) compared to blood tests and clinical scoring systems for the evaluation of histopathologic severity in patients with primary sclerosing cholangitis (PSC).
Materials
Fifty-one patients (M/F 37/14, mean age 41 years) with PSC who underwent MRI and liver histopathology were included in this IRB-approved retrospective study. Two radiologists independently graded the severity of biliary abnormalities on magnetic resonance cholangiopancreatography (MRCP) using a standardized scoring system, parenchymal enhancement, and diffusion-weighted imaging (DWI) signal. Liver function tests, Mayo Risk score, APRI, FIB-4 Index, MELD, and Child–Pugh scores were recorded. Histopathology was assessed using a modified Nakanuma’s scoring system. Correlation and diagnostic performance of MRI scores and blood tests for assessment of PSC histopathologic disease severity were evaluated.
Results
Findings of cirrhosis and portal hypertension were the only imaging features diagnostic of advanced PSC (stages 3 and 4) with AUC up to 0.90 (p < 0.001) for both observers. Parenchymal enhancement and overall qualitative biliary ductal abnormality identified advanced PSC stage with AUC up to 0.767 (p = 0.002) only for one observer. There was weak correlation between the overall qualitative biliary ductal abnormality on MRCP and histopathologic stage (r = 0.36, p = 0.01) for one observer. FIB-4 index, Child–Pugh, MELD, Mayo Risk, APRI, and alkaline phosphatase demonstrated good to excellent performance for advanced PSC stage (AUCs 0.672–0.915, p < 0.045).
Conclusions
MRI findings of cirrhosis/portal hypertension, blood tests, and clinical scoring systems had high performance for advanced histopathologic PSC stage diagnosis, while the severity of biliary abnormalities on MRI did not.
Similar content being viewed by others
Abbreviations
- ADC:
-
Apparent diffusion coefficient
- APRI:
-
AST to Platelet Ratio Index
- DWI:
-
Diffusion-weighted imaging
- EHD:
-
Extrahepatic duct
- ERC:
-
Endoscopic retrograde cholangiography
- HASTE:
-
Half-Fourier acquisition single-shot turbo spin echo imaging
- HBP:
-
Hepatobiliary phase
- LAVA:
-
Liver acquisition with volume acceleration
- LIH:
-
Left intrahepatic duct
- LLIHD:
-
Left lateral intrahepatic duct
- LMIHD:
-
Left medial intrahepatic duct
- MELD:
-
Model for end-stage liver disease
- MRCP:
-
Magnetic resonance cholangiopancreatography
- MRI:
-
Magnetic resonance imaging
- PSC:
-
Primary sclerosing cholangitis
- RAIHD:
-
Right anterior intrahepatic duct
- ROI:
-
Region of interest
- RIH:
-
Right intrahepatic duct
- RPIHD:
-
Right posterior intrahepatic duct
- SSFSE:
-
Single-shot fast spin echo
- VIBE:
-
Volumetric interpolated breath-hold examination
References
Silveira, M.G. and K.D. Lindor, Primary sclerosing cholangitis. Can J Gastroenterol, 2008. 22(8): p. 689-98.
Ni Mhuircheartaigh, J.M., et al., Early Peribiliary Hyperenhancement on MRI in Patients with Primary Sclerosing Cholangitis: Significance and Association with the Mayo Risk Score. Abdom Radiol (NY), 2017. 42(1): p. 152-158.
Nilsson, H., et al., Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J Magn Reson Imaging, 2014. 39(4): p. 879-86.
Nolz, R., et al., Diagnostic workup of primary sclerosing cholangitis: the benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography. Clin Radiol, 2014. 69(5): p. 499-508.
Olsson, R., et al., High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology, 2005. 129(5): p. 1464-72.
Ponsioen, C.Y., et al., Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology, 2016. 63(4): p. 1357-67.
Ponsioen, C.Y., et al., Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut, 2002. 51(4): p. 562-6.
Lindstrom, L., et al., Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol, 2013. 11(7): p. 841-6.
Stanich, P.P., et al., Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis, 2011. 43(4): p. 309-13.
Eaton, J.E., et al., Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol, 2016. 31(6): p. 1184-90.
Ruiz, A., et al., Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology, 2014. 59(1): p. 242-50.
Portmann, B. and Y. Zen, Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology, 2012. 60(2): p. 236-48.
de Vries, E.M., et al., Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. J Hepatol, 2015. 63(5): p. 1212-9.
Petrovic, B.D., et al., Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci, 2007. 52(12): p. 3499-506.
Corpechot, C., et al., Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology, 2014. 146(4): p. 970-9; quiz e15-6.
Hinrichs, H., et al., Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC). Eur Radiol, 2016. 26(4): p. 1116-24.
Kovac, J.D., et al., MR imaging of primary sclerosing cholangitis: additional value of diffusion-weighted imaging and ADC measurement. Acta Radiol, 2013. 54(3): p. 242-8.
Kim, W.R., et al., The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology, 1999. 29(6): p. 1643-8.
Olsson, R.G. and M.S. Asztely, Prognostic value of cholangiography in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol, 1995. 7(3): p. 251-4.
Rudolph, G., et al., Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol, 2009. 51(1): p. 149-55.
Stiehl, A., et al., Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol, 2002. 36(2): p. 151-6.
Vesterhus, M., et al., Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology, 2015. 62(1): p. 188-97.
Dave, M., et al., Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology, 2010. 256(2): p. 387-96.
Frydrychowicz, A., et al., Gadoxetic acid-enhanced T1-weighted MR cholangiography in primary sclerosing cholangitis. J Magn Reson Imaging, 2012. 36(3): p. 632-40.
Ringe, K.I., et al., Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion. J Magn Reson Imaging, 2014. 40(1): p. 106-12.
Schramm, C., et al., Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology, 2017. 66(5): p. 1675-1688.
Keller, S., et al., Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis. PLoS One, 2018. 13(3): p. e0193929.
Keller, S., et al., Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis. Eur Radiol, 2019. 29(2): p. 818-828.
Tenca, A., et al., The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. Liver Int, 2018.
Kim, W.R., et al., A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc, 2000. 75(7): p. 688-94.
Kamath, P.S., W.R. Kim, and G. Advanced Liver Disease Study, The model for end-stage liver disease (MELD). Hepatology, 2007. 45(3): p. 797-805.
Kim, B.K., et al., Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int, 2010. 30(4): p. 546-53.
Durand, F. and D. Valla, Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol, 2005. 42 Suppl(1): p. S100-7.
Nakanuma, Y., et al., Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int, 2010. 60(3): p. 167-74.
Lemoinne, S., et al., Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol, 2019.
Corpechot, C., Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases. Clin Liver Dis, 2016. 20(1): p. 143-58.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Song, C., Lewis, S., Kamath, A. et al. Primary sclerosing cholangitis: diagnostic performance of MRI compared to blood tests and clinical scoring systems for the evaluation of histopathological severity of disease. Abdom Radiol 45, 354–364 (2020). https://doi.org/10.1007/s00261-019-02366-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-019-02366-9